Fujimoto, Nobukazu
Okayama Rosai Hospital
3 papers on CoChatORCID 0000-0002-4516-0433
Most cited papers
- Verified
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet
Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies
Cited by 1,215
- Verified
Prognostic Significance of the Lymphocyte-to-Monocyte Ratio in Patients with Malignant Pleural Mesothelioma
Yamagishi, T., Fujimoto, N., Nishi, H., Miyamoto, Y., Hara, N., Asano, M., Fuchimoto, Y., Wada, S., Kitamura, K., Ozaki, S., et al. (2015) · Lung Cancer
Inflammatory Biomarkers in Disease PrognosisOccupational and environmental lung diseases
Cited by 61
- Verified
Catamenial pneumothorax due to heterotopic endometriosis in the pericardium
Takigawa, Y., Mizuno, D., Iga, N., & Fujimoto, N. (2021) · BMJ Case Reports
Endometriosis Research and TreatmentPleural and Pulmonary Diseases
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free